1646-32-8

Basic information

• Product Name: 1-(5-CHLOROBENZO[B]FURAN-2-YL)ETHAN-1-ONE
• Synonyms: 1-(5-CHLOROBENZO[B]FURAN-2-YL)ETHAN-1-ONE;Ethanone, 1-(5-chloro-2-benzofuranyl)-;1-(5-Chlorobenzofuran-2-yl)ethanone;1-(5-Chlorobenzofuran-2-yl)ethan-1-one
• CAS NO: 1646-32-8
• Molecular Formula: C₁₀H₇ClO₂
• Molecular Weight: 194.61
• Mol File: 1646-32-8.mol
• Article Data: 9

Chemical Properties

• Melting Point: 97 °C
• Boiling Point: 293 °C at 760 mmHg
• Flash Point: 131 °C
• Appearance: /
• Density: 1.298 g/cm³
• Vapor Pressure: 0.00177mmHg at 25°C
• Refractive Index: 1.6
• CAS DataBase Reference: 1-(5-CHLOROBENZO[B]FURAN-2-YL)ETHAN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-CHLOROBENZO[B]FURAN-2-YL)ETHAN-1-ONE(1646-32-8)
• EPA Substance Registry System: 1-(5-CHLOROBENZO[B]FURAN-2-YL)ETHAN-1-ONE(1646-32-8)

Safety Data

• Hazardous Substances Data: 1646-32-8(Hazardous Substances Data)

Usage

General Description

1-(5-CHLOROBENZO[B]FURAN-2-YL)ETHAN-1-ONE is a chemical compound that falls under the category of organohalogen compounds. The International Union of Pure and Applied Chemistry (IUPAC) name of this chemical is 1-(5-chlorobenzofuran-2-yl)ethan-1-one. Due to its complex structure, it is often used in research and development applications within the science and pharmaceutical fields. More specific data such as it's detailed physical and chemical properties, toxicity, or practical uses isn't widely available due to the specific and specialized nature of the compound. It's always important to handle such compounds with care, following appropriate safety procedures, due to their potential hazards.

InChI:InChI=1/C10H7ClO2/c1-6(12)10-5-7-4-8(11)2-3-9(7)13-10/h2-5H,1H3

Upstream product

• 78-95-5 chloroacetone 
• 635-93-8 5-chlorosalicyclaldehyde 
• 67-64-1 acetone 
• 638-07-3 ethyl (2-chloroaceto)acetate 
• 598-31-2 1-bromoacetone 
• 1761-61-1 5-bromosalicyclaldehyde 

Downstream Products

• 58583-63-4 1-(5-chloro-2-benzofuranyl)-3-(3,5-xylyl)-2-propen-1-one 
• 62763-16-0 1-(5-methyl-2-benzofuranyl)-3-(3,5-xylyl)-2-propen-1-one 
• 7039-74-9 2-bromoacetyl-5-chlorobenzofuran 
• 1117816-34-8 ethyl 2-[1,2-diaza-3-(5-chlorobenzo[d]furan-2-yl)but-2-enylidine]-3-phenyl-1,3,4-thiadiazolin-5-carboxylate 
• 39178-59-1 5-chloro-2-ethylbenzofuran 

Relevant articles and documents

Synthesis and Anti-Cholinesterase Activity of Novel Glycosyl Benzofuranylthiazole Derivatives

Abstract: A new series of glycosyl benzofuranylthiazole derivatives were designed, synthesized, characterized, and evaluated as potential candidates to treat Alzheimer’s disease. The compounds have been synthesized by the cyclocondensation of glycosyl thiourea with a variety of 2-(bromoacetyl)benzofurans. The reaction conditions have been optimized, and good yields (79–95%) have been obtained. The synthesized compounds showed different degrees of cholinesterase inhibitory activity.

TBAI/TBHP mediated oxidative cross coupling of ketones with phenols and carboxylic acids: Direct access to benzofurans

TBAI/TBHP mediated oxidative cross coupling of phenols and carboxylic acids with ketones has been reported under metal-free, base free, solvent free conditions enabling environmentally benign synthesis of aryloxyketones, acyloxy ketones and benzofurans. Phenoxyketones and acyloxylcarbonyl compounds were synthesized in good to high yields, where as benzofurans were synthesized in moderate yields. This method is operationally simple, works under mild conditions, using commercially available as well as inexpensive TBAI and an oxidant TBHP.

NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

The invention relates to novel arylalkenylpropargylamine derivatives of general formula (I) or enantiomers or diastereomers thereof or salts, optionally pharmaceutically acceptable salts, or solvates of any of these. The compounds can be used in treating or preventing a disease or condition in a mammal related to monoamine oxidase dysfunction, especially in neurodegenerative diseases, e.g. Parkinson's disease, Alzheimer's disease or Huntington's disease.